Fig. S1

Fig. S1 Most hematopoietic and vascular markers assessed are expressed normally in nz171 mutants. (A-D) Expression of hematopoietic markers in whole-mount embryos as detected by in situ hybridization. Anterior to the left (except B, top panels: posterior view). (A) scl expression in wild-type and nz171 mutant embryos, as indicated on the panels. At 30 h.p.f., expression levels of scl in nz171 embryos are similar to those in wild type, and at 48 h.p.f. scl expression is still observed in the ICM region, suggesting that it has not been downregulated as observed in wild-type embryos. (B) gata2 expression in 6-somite, 18 h.p.f. and 24 h.p.f. wild-type and nz171 embryos as indicated on the panels. gata2 transcript levels in nz171 mutants are similar to wild type levels. (C) Expression of various hematopoietic genes in wild-type and nz171 mutant embryos, as indicated on the panels. The presence of myeloid precursors in the ALM of nz171 embryos is indicated by the normal expression of cebpa and c-myb in this area. (D) Vascular markers fli1 and flk1 are expressed relatively normally in nz171 mutants at 24 h.p.f. (E) Schematic illustrating the expression status of hematopoietic genes in nz171 mutants according to when they are expressed developmentally. Green, gene expression not affected; orange, reduced; red, completely absent.